Posted on: 31 January 2013
The Trinity College School of Pharmacy & Pharmaceutical Sciences has moved to Trinity Biomedical Sciences Institute (TBSI), a state-of-the-art research facility supported by HEA’s PRTLI Cycle 5. “This is an exciting development for our School which allows us to excel in pharmaceutical research and development. This new facility will provide us with high-tech technology and interdisciplinary collaborations to support our research,” said Professor Marek Radomski. Radomski, Head of this School and Director of the Centre for Cancer Drug Discovery in TBSI, is a highly-cited pharmacologist interested in nanomedical research.
To mark the opening, the School recently held a Research Symposium in TBSI. The Symposium started with presentations honouring and celebrating the research achievements of Professor Owen Corrigan. Corrigan is the founder of modern pharmaceutical technology research in Ireland. Following the presentations, a keynote lecture was delivered by Professor Patrick Vallance. Vallance is the President of Pharmaceuticals R&D at Glaxo Smith Kline (GSK). He discussed how the process of discovery advances drug development.
Following the lecture, Principal Investigators from the School of Pharmacy & Pharmaceutical Sciences highlighted their innovative and groundbreaking research including nanomedicine and cancer research. “Nanomedicine uses super tiny materials (nanomaterials) for prevention and new treatment of human diseases” explained Radomski.
The Symposium was followed by a tour of the new research facilities (www.tcd.ie/biosciences; www.tcd.ie/pharmacy).
For full details of the programme:
http://www.pharmacy.tcd.ie/assets/img/Research%20Day%20Symposium%20Invite.jpg
